<?xml version="1.0" encoding="UTF-8"?>
<p>Current antifungal therapy continues to present several limitations due to safety issues, pharmacokinetics, narrow activity spectrum and low number of targets [
 <xref rid="B9-antibiotics-10-00592" ref-type="bibr">9</xref>] For example, polyenes and amphotericin B are highly toxic whereas azoles, like fluconazole, only present a fungistatic effect. In addition, the emergence of resistant strains also compromises the effectiveness of these antifungals [
 <xref rid="B10-antibiotics-10-00592" ref-type="bibr">10</xref>,
 <xref rid="B11-antibiotics-10-00592" ref-type="bibr">11</xref>].
</p>
